Similar articles

• Antiviral and side effects of interferons produced by recombinant DNA techniques as tested in rhesus monkeys.

  Schellekens H, van Eerd PM, de Reus A, Weck PK, Stebbing N. Schellekens H, et al. Antiviral Res. 1982 Oct;2(5):313-8. doi: 10.1016/0166-3542(82)90054-7. Antiviral Res. 1982. PMID: 6817709
• Prevention of vaccinia lesions in Rhesus monkeys by human leucocyte and fibroblast interferon.

  Weimar W, Stitz L, Billiau A, Cantell K, Schellekens H. Weimar W, et al. J Gen Virol. 1980 May;48(1):25-30. doi: 10.1099/0022-1317-48-1-25. J Gen Virol. 1980. PMID: 6155433
• Biologicals for cancer treatment: interferons.

  Oldham RK. Oldham RK. Hosp Pract (Off Ed). 1985 Dec 15;20(12):71-4, 78-81, 85-6 passim. doi: 10.1080/21548331.1985.11703206. Hosp Pract (Off Ed). 1985. PMID: 2415542 No abstract available.
• A brief history of the use of interferons as treatment of multiple sclerosis.

  Jacobs L, Johnson KP. Jacobs L, et al. Arch Neurol. 1994 Dec;51(12):1245-52. doi: 10.1001/archneur.1994.00540240089022. Arch Neurol. 1994. PMID: 7986181 Review.
• The interferon system as a basis for antiviral therapy or prophylaxis.

  Billiau A. Billiau A. Antiviral Res. 1985;Suppl 1:131-40. doi: 10.1016/s0166-3542(85)80020-6. Antiviral Res. 1985. PMID: 3936410 Free PMC article. Review. No abstract available.